A detailed history of Bayesian Capital Management, LP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bayesian Capital Management, LP holds 11,900 shares of BMY stock, worth $632,961. This represents 0.06% of its overall portfolio holdings.

Number of Shares
11,900
Holding current value
$632,961
% of portfolio
0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $478,975 - $630,581
11,900 New
11,900 $494,000
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $5.08 Million - $6.06 Million
104,800 New
104,800 $5.38 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $943,727 - $1.1 Million
-17,597 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $217,568 - $254,852
3,677 Added 26.42%
17,597 $1.04 Million
Q2 2021

Aug 13, 2021

SELL
$61.91 - $67.42 $2.74 Million - $2.98 Million
-44,270 Reduced 76.08%
13,920 $930,000
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $284,238 - $319,684
4,790 Added 8.97%
58,190 $3.67 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $2.02 Million - $2.29 Million
35,000 Added 190.22%
53,400 $3.31 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $321,608 - $356,384
-5,600 Reduced 23.33%
18,400 $1.11 Million
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $1.32 Million - $1.54 Million
24,000 New
24,000 $1.41 Million
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $2.58 Million - $2.85 Million
-57,800 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $2.61 Million - $3.11 Million
57,800 New
57,800 $2.76 Million
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $1.32 Million - $1.64 Million
-26,100 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $1.56 Million - $1.8 Million
26,100 New
26,100 $1.65 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.